A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of MCS-5 in Treating Male Oligoasthenospermia (MCS_MOS)
Latest Information Update: 27 Dec 2023
Price :
$35 *
At a glance
- Drugs MCS 5 (Primary)
- Indications Male infertility
- Focus Therapeutic Use
- Acronyms MCS_MOS
- Sponsors Health Ever Bio-Tech
- 18 Dec 2023 Status changed from recruiting to discontinued.
- 29 Dec 2015 New trial record